DiaMedica Therapeutics Inc (DMA) Analysts See $-0.01 EPS

November 15, 2017 - By Darrin Black

 DiaMedica Therapeutics Inc (DMA) Analysts See $ 0.01 EPS

Investors wait DiaMedica Therapeutics Inc (CVE:DMA) to report on December, 5. its quarterly earnings Wall Street analysts expect $-0.01 earnings per share, $0.00 or 0.00 % from last year’s $-0.01 same quarter earnings. DiaMedica Therapeutics Inc’s Wall Street analysts see 0.00 % EPS growth, taking into account the $-0.01 EPS reproted in the previous quarter, It closed at $0.39 lastly. It is down 0.00% since November 15, 2016 and is . It has underperformed by 16.70% the S&P500.

DiaMedica Therapeutics Inc is a Canada clinical-stage biopharmaceutical company, which focuses on recombinant proteins and monoclonal antibodies. The company has market cap of $48.27 million. The Firm focuses on the discovery and development of treatments for stroke and other vascular diseases. It currently has negative earnings. It operates through segment, which is discovery and development of recombinant proteins and monoclonal antibody technology applications to treat large unmet diseases, including acute vascular disease of the brain, kidneys and heart.

More notable recent DiaMedica Therapeutics Inc (CVE:DMA) news were published by: Finance.Yahoo.com which released: “DiaMedica: A Key Player in the area of AIS and DKD” on February 15, 2017, also Globenewswire.com with their article: “DiaMedica Therapeutics Announces the Early Exercise of Warrants from Strategic …” published on October 27, 2017, Globenewswire.com published: “DiaMedica Therapeutics Announces Publication of Positive Clinical Results for …” on November 07, 2017. More interesting news about DiaMedica Therapeutics Inc (CVE:DMA) were released by: Globenewswire.com and their article: “DiaMedica Announces the Initiation of Phase 2 Trial Evaluating DM199 …” published on September 11, 2017 as well as Globenewswire.com‘s news article titled: “DiaMedica Announces Dr. Robert Stanton as Scientific Advisor for Upcoming …” with publication date: October 31, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.